Correlation between interferon production and clinical disease activity in patients with multiple sclerosis

Journal of Clinical Immunology

Volumn 17, Issue 4, 1997, Pages 293-300

  Dettke, M ^a,c   Scheidt, P ^b   Prange, H ^b   Kirchner, H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Interferon ; Interferon ; Longitudinal study; Multiple sclerosis

Indexed keywords

ALPHA INTERFERON; CONCANAVALIN A; GAMMA INTERFERON; INTERFERON; VIRUS ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; INTERFERON INDUCTION; INTERFERON PRODUCTION; MALE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION;

ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON TYPE II; INTERFERON-ALPHA; LEUKOCYTES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES;

EID: 0030787571     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1027374615106     Document Type: Article

References (43)

1. Boyle EA, McGeer PL: Cellular immune response in multiple sclerosis plaques. Am J Pathol 137:575-584, 1990
2. Hartung HP: Immune-mediated demyelination. Ann Neurol 33: 563-567, 1993
3. Hintzen RQ, Polman CH, Lucas CJ, Lier van RA: Multiple sclerosis: immunological findings and possible implications for therapy. J Neuroimmunol 39:1-10, 1992
4. Panitch HS, Hirsch RL, Haley AS, Johnson KP: Exacerbation of multiple sclerosis in patients treated with gamma interferon. Lancet 1:893-895, 1987
5. Panitch HS, Hirsch RL, Schindler J, Johnson KP: Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system. Neurology 37:1097-1102, 1987
6. Fierz W, Endler B, Reske K, Wekerle H, Fontana A: Astrocytes as antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells via immune interferon and its effect on antigen presentation. J Immunol 134:3785-3793, 1985
7. Raine CS: Multiple sclerosis: Immune system molecule expression in the central nervous system. J Neuropathol Exp Neurol 53:328-337, 1994
8. Arnason BGW: Interferon beta in multiple sclerosis. Clin Immunol Immunopathol 81:1-11, 1996
9. AUSTIMS Research Group: Interferon-α and transfer factor in the treatment of multiple sclerosis: A double blind, placebo-controlled trail. J Neurol Neurosurg Psychiat 52:566-574, 1989
10. Jacobs L, Cookfair D, Rudick R, Hemdon R, Richert J, Salazar A, Fischer J, Granger C, Simon J, Goodkin D, MSCR Group: Results of a phase III trail of intramuscular recombinant beta interferon as treatment for multiple sclerosis. Ann Neurol 36:259, 1994 (abstr)
11. IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Interferon beta-Ib in the treatment of multiple sclerosis: Final outcome of the randomized controlled trail. Neurology 45:1277-1285, 1995
12. Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Geuna M, Bergamini L, Bergamasco B: Chronic systemic high-dose recombinant interferon alpha-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte gamma production in relapsing-remitting multiple sclerosis. Neurology 44:406-413, 1994
13. Sibley MK, Bamford CR, Clark K: Clinical viral infections and multiple sclerosis. Lancet 1:1313-1315, 1985
14. Panitch HS: Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 36 (Suppl):S25-S28, 1994
15. Trotter JL, Clifford DB, Mclnnis JE, Griffeth RC, Bruns KA, Perlmutter MS, Anderson CB, Collins KG, Banks G, Hicks BC: Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol 25:172-178, 1989
16. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE: Tumor necrosis factor-α production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 3:523-531, 1992
17. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Lüer W, Helwig A, Poser S: Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 37:82-88, 1995
18. Mokhtarian F, Shi Y, Shirazian D, Morgante L, Miller A, Grob D: Defective production of anti-inflammatory cytokine, TGF beta by T cell lines of patients with active multiple sclerosis. J Immunol 152:6003-6010, 1994
19. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Fhers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: Guidelines for research protocol. Ann Neurol 13:227-231, 1983
20. Kurtzke JF: Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33:1444-1452, 1983
21. Leroux M, Schindler L, Braun R, Doer HW, Geisen HP, Kirchner H: A whole-blood lymphoproliferalion assay for measuring cellular immunity against Herpes virus. J Immunol Methods 79:251-262, 1985
22. Neustock P, Kruse A, Bock S, Pierre BS, Kirchner H: Deficient interferon-α response of newborns in comparison to adults. Lymphokine Cytokine Res 12:109-114, 1993
23. Weller M, Stevens A, Sommer N, Melms A, Dichgans J, Wiethölter H: Comparative analysis of cytokine patterns in immunological, infectious, and oncological neurological disorders. J Neurol Sci 104:215-221, 1991
24. Kastrukoff LF, Oger JJ, Tourtellotte WW, Sacks SL, Berkowitz J, Paty DW: Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. II. Immunologic evaluation. Neurology 41:1936-1941, 1991
25. + in patients with multiple sclerosis. Eur Neurol 33:152-155, 1993
26. Hertzog PL, Wright A, Harris G, Linnane AW, Mackay IR: Intermittent interferonemia and interferon responses in multiple sclerosis. Clin Immunol Immunopathol 58: 18-32, 1991
27. Rudick RA, Ransohoff RM: Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity. Arch Neurol 49:265-270, 1992
28. Huberman M, Shalit F, Roth-Deri I, Gutman B, Kott E, Sredni B: Decreased IL-3 production by peripheral blood mononuclear cells in patients with multiple sclerosis. Ann Neurol Sci 118:79-82, 1993
29. Beck J, Rondot P, Catinot L, Falcoff H, Kirchner H, Wietzerbin J: Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol Scand 78:318-323, 1988
30. Haahr S, Moller-Larsen A, Justesen J, Pedersen E: Interferon induction, 2′-5′oligo A synthetase and lymphocyte subpopulations in out-patients with multiple sclerosis in a longitudinal study. Acta Neurol Scand 73:345-351, 1986
31. DeGroote D, Zangerle PF, Gevaert Y, Passotte MF, Beguin Y, Noizat-Pirenne F, Pirenne J, Gathy R, Lopez M, Dehart I, Igot D, Baudrihaye M, Delacroix D, Franchimont P: Direct stimulation of cytokines (IL1 β, TNF α, IL6, IL2, IFN γ and GM CSF) in whole blood. I Comparison with isolated PBMC stimulation. Cytokine 3:239-248, 1992
32. Cannella B, Cross AH, Raine CS: Upregulation and coexpression of adhesion molecules correlate with relapsing autoimmune demyelination in the central nervous system. J Exp Med 172:1521-1524, 1990
33. McCarron RM, Wang L, Racke MK, McFarlin DE, Spatz M: Cytokine-rcgulated adhesion between encephalitogenic T lymphocytes and cerebrovascular endothelial cells. J Neuroimmunol 43:23-30, 1993
34. Sharief MK, Hentges R: Association between tumor necrosis factor and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-472, 1991
35. Olsson T: Cytokines in neuroinflammatory disease: Role of myelin autoreactive T cell production of interferon gamma. J Neuroimmunol 40:211-218, 1992
36. Imamura K, Suzumura A, Hayashi F, Marunouchi T: Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand 87:281-285, 1993
37. Noronha A, Toscas A, Jensen MA: Interferon-β decreases T cell activation and interferon-γ production in multiple sclerosis. J Neuroimmunol 46:145-153, 1993
38. Abu-Khabar KS, Armstrong JA, Ho M: Type I interferons (IFN-alpha and -beta) suppress cytotoxin (tumor necrosis factor-alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cells. J Leukocyte Biol 52:165-172, 1992
39. Tilg H, Vogel W, Dinarello CA: Interferon-α induces circulating tumor necrosis factor receptor p55 in humans. Blood 2:433-435, 1995
40. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immumol 151:1548-1561, 1993
41. Selmaj K, Papierz W, Glabinski A, Kohno T: Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 56:135-141, 1995
42. Rieckmann P, Martin S, Weiselbraun I, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Lüer W, Helwig A, Poser S: Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Neurology 44:2367-2372, 1994
43. Fillippi M, Paty DW, Kappos L, Barkhof F, Compston DA, Thompson AJ, Zhao GJ, Wiles CM, McDonald WI, Miller DH: Correlations between changes in disability and T2-weight brain activity in multiple sclerosis: A follow-up study. Neurology 45:255-260, 1995